Veerhealth Care share price
BSE: 511523Pharmaceuticals & BiotechnologySmall Cap
Last close ₹49.27up ₹0.16 (0.33%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹49.11.
52-week range of traded prices to 23 Oct 2026
₹16.70Low, 1 Feb 2026₹52.00High, 15 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹99 Cr3,569th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 64.4
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹0.31 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 53.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 4.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 6.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹0.31 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 8.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 11.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 0.20
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,08,200
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 13 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹25 Crup 48.71%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹1.23 CrQuarter to Mar 2026: −₹0.35 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 4.9%
Revenue by year
Peak revenue ₹32 Cr, year to Mar 2026
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 10 years shown
| ₹ crore | Sep 2024Filed 14 Nov | Dec 2024Filed 12 Feb | Mar 2025Filed 13 Jun | Jun 2025Filed 12 Aug | Sep 2025Filed 12 Nov | Dec 2025Filed 14 Feb | Mar 2026Filed 30 May | Jun 2026Filed 13 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.1 | 3.8 | 5.6 | 4.5 | 4.0 | 7.3 | 16.8 | 24.9 |
| Net profit | 0.3 | 0.1 | −0.1 | 0.2 | 0.3 | 0.4 | −0.4 | 1.2 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 5.8% | 1.8% | −1.8% | 5.4% | 6.3% | 5.6% | −2.1% | 4.9% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Health Pharma Products, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 26% of 247 trading days over the last year.
LowestHighest
Its median60.1Industry median28.1
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 98% of 1,782 trading days since Nov 2018.
LowestHighest
Its median1.1Industry median2.8
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.23.3
At or below today's level on 3% of 742 trading days over the last 3 years.
LowestHighest
Its median37.4Industry median18.7
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +64.5% | +39.0% | +18.4% | 0.0% |
| 3 years | +26.2% | −29.9% | +80.1% | 0.0% |
| 5 years | +39.6% | −0.4% | +40.1% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 and 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 1, 3 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2026.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Veerhealth Care in market cap. 2 companies in the table last traded before then: their rows are priced on their last trade.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Tyche IndustriesTYCHE | 107 | 24.0 | 0.8 | – | −21.0% | −63.5% | 3.2% | −2.5% | 3.36% |
 Alpa LaboratoriesALPA | 104 | – | 0.6 | – | +0.5% | – | – | −1.8% | 0.00% |
 Pharmaids PharmaceuticalsPHARMAID | 102 | – | 2.1 | – | +18.5% | – | −8.5% | −15.8% | 0.00% |
 Sotac PharmaceuticalsSOTAC | 102 | 17.6 | 1.7 | – | +0.1% | −28.2% | 10.3% | – | 0.22% |
 Parmax PharmaPARMAX | 94 | – | – | – | −17.6% | – | – | −70.0% | 0.00% |
 Amwill Health CareAMWILL | 90 | 7.9 | 1.1 | – | +12.1% | +6.4% | 15.2% | – | 1.11% |
 Concord DrugsCONCORD | 90 | 43.7 | – | – | +82.5% | +380.5% | 5.0% | 7.1% | 0.00% |
 Vaishali PharmaVAISHALI | 90 | 20.2 | 1.3 | 25.2 | – | – | 6.6% | 4.2% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
Veerhealth Care share price by year
Each calendar year to 2025.Veerhealth Care share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 19.33 | −1.0% | 23.05 | 10.07 |
| 2024 | 19.52 | −4.2% | 28.78 | 17.96 |
| 2023 | 20.38 | +76.1% | 21.91 | 8.61 |
| 2022 | 11.58 | +85.2% | 11.58 | 5.00 |
| 2021 | 6.25 | +64.5% | 6.45 | 3.59 |
| 2020 | 3.80 | −15.6% | 5.18 | 2.75 |
| 2019 | 4.50 | 0.0% | 4.90 | 3.60 |
| 2018 | 4.50 | −52.5% | 11.18 | 4.30 |
| 2017 | 9.48 | – | 9.48 | 4.87 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 49.00 | 49.88 | 48.51 | 49.27 | 49.22 | 1,08,200 |
| 22 Oct 2026 | 49.60 | 49.64 | 48.20 | 49.11 | 48.98 | 64,923 |
| 21 Oct 2026 | 49.70 | 49.75 | 48.25 | 49.46 | 49.30 | 1,94,592 |
| 19 Oct 2026 | 49.70 | 49.74 | 48.25 | 49.12 | 49.11 | 53,461 |
| 16 Oct 2026 | 49.89 | 49.89 | 48.50 | 49.69 | 49.33 | 1,15,222 |
| 15 Oct 2026 | 49.67 | 49.86 | 48.75 | 49.64 | 49.43 | 20,567 |
| 14 Oct 2026 | 49.90 | 49.90 | 48.70 | 49.68 | 49.56 | 95,230 |
| 13 Oct 2026 | 49.05 | 50.09 | 48.73 | 49.73 | 49.33 | 31,460 |
| 12 Oct 2026 | 50.25 | 50.25 | 48.71 | 49.87 | 49.49 | 45,520 |
| 9 Oct 2026 | 49.78 | 49.78 | 48.50 | 49.57 | 49.33 | 64,760 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 22 Sep 2023 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 29 Nov 2016 | Share count change | – | The company changed its share count by an amount the filing does not state, so earlier prices are not shown. |
| 21 Nov 2016 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Where an event has no factor that can be worked out, the chart leaves out the closes before it. Any other event is noted and not adjusted for.
Company details
- Legal name
- Veerhealth Care Limited
- BSE code
- 511523
- ISIN
- INE882C01035
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Sep 1994
- Face value
- ₹10
- CIN
- L65910MH1992PLC067632
- Corporate identity number, the registrar of companies' code for it